Atilla Soran, MD, MPH

Articles by Atilla Soran, MD, MPH

84 Exceptional Responders in De Novo Metastatic Breast Cancer (dnMBC) Drug Cessation in Patients With HER2-Positive Metastatic Breast Cancer; Multicenter Retrospective Study

ByMutlu Dogan,Berk Goktepe,Mehmet Bilici,Sercan Aksoy,Fatih Selcukbiricik,Ali Alkan,Arzu Oguz,Arzu Yasar,Naziye Ak,Betul Ersoz,Lutfi Dogan,Merve Tokocin,Yasemin Evlendi,Ozlem Soran,Qurat Ul Ain Sabih,Julia Foldi,Atilla Soran, MD, MPH

June 6th 2026

Extended drug cessation appears feasible in exceptional responders with HER2+ de novo metastatic breast cancer, with significantly better survival compared with non-exceptional responders.

59 Are Choosing Wisely Guidelines Applicable to Patients With a High Ki-67 Proliferation Index and Magee Equation Score?

ByLeslie Elmore,Neil Carleton,Michael S. Cowher,Rohit Bhargava,Emilia Diego,Kristin Lupinacci,Meaghan Marley,Qurat Ul Ain Sabih,Atilla Soran, MD, MPH,Jennifer Steiman,Ronald Johnson,Erin Bayley,Priscilla F. Mcauliffe, MD, PhD

May 17th 2025

90 Contralateral Risk Reduction Mastectomy in Patients With Unilateral Breast Cancer: A Multinational and Multidisciplinary Survey—Physicians’ Perspective

ByAtilla Soran, MD, MPH,Kazim Senol,Schlomo Schneebaum,Shigeru Imoto,Carole Mathelin,Alexander Mundinger,Meltem Selam,Vahit Ozmen

April 21st 2025

91 Adverse Effects and Financial Burden of Radiation Therapy in Patients With T3N0M0 Luminal Breast Cancer

ByZeynep Ozlem Soran,Allison Brophy,Lily Kass,Berkay Demirors,Hayeon Kim,Atilla Soran, MD, MPH,John Austin Vargo,Parul Barry

April 20th 2025

43 Factors Affecting Survival in Solitary Bone-Only De Novo Stage IV Metastatic Breast Cancer

ByKazim Senol,Aykut Soyder,Ahmet Dag,Didem Can Trabulus,Ahmet Bilici,Mutlu Dogan,Hasan Karanlık,Serdar Ozbas,Atilla Soran, MD, MPH

April 26th 2023

43 Early Detection of Breast Cancer–Related Lymphedema: Accuracy of Indocyanine Green Lymphography Compared With Bioimpedance Spectroscopy and Symptoms

ByAtilla Soran, MD, MPH,Fuat B. Bengur,Wendy Rodriguez,Efe Sezgin

May 6th 2022

Lymphedema Prevention and Early Intervention: A Worthy Goal

ByAtilla Soran, MD, MPH,David N. Finegold, MD,Adam M. Brufsky, MD, PhD

March 12th 2012

The etiology and risk factors of breast cancer–related lymphedema (BCRL) are multifactorial and not fully understood.

Latest Updated Articles

Lymphedema Prevention and Early Intervention: A Worthy Goal
March 12th 2012

Atilla Soran, MD, MPH

Articles by Atilla Soran, MD, MPH

84 Exceptional Responders in De Novo Metastatic Breast Cancer (dnMBC) Drug Cessation in Patients With HER2-Positive Metastatic Breast Cancer; Multicenter Retrospective Study

59 Are Choosing Wisely Guidelines Applicable to Patients With a High Ki-67 Proliferation Index and Magee Equation Score?

90 Contralateral Risk Reduction Mastectomy in Patients With Unilateral Breast Cancer: A Multinational and Multidisciplinary Survey—Physicians’ Perspective

91 Adverse Effects and Financial Burden of Radiation Therapy in Patients With T3N0M0 Luminal Breast Cancer

43 Factors Affecting Survival in Solitary Bone-Only De Novo Stage IV Metastatic Breast Cancer

43 Early Detection of Breast Cancer–Related Lymphedema: Accuracy of Indocyanine Green Lymphography Compared With Bioimpedance Spectroscopy and Symptoms

Lymphedema Prevention and Early Intervention: A Worthy Goal

Latest Updated Articles

Trending on CancerNetwork

FDA Approves Afami-cel in Metastatic Synovial Sarcoma

The Moonlight Shift: Dr Joshua Richter on Myeloma, Myths, and the C-Word

Current Treatment Landscape of HER2-Positive Metastatic Breast Cancer and Phase 3 Trial Overview

How Are Key Lymphoma Data From ASCO and EHA 2026 Shaping Treatment?

TROPION-Breast01 and Comparative ADC Data